112 results on '"Vigneault E"'
Search Results
2. A randomized Phase 3 trial of Metformin in patients initiating androgen deprivation therapy as PRevention and Intervention of MEtabolic syndrome: The PRIME Study
3. Long-Term Outcomes of NRG/RTOG 0126, a Randomized Trial of High Dose (79.2 Gy) vs. Standard Dose (70.2 Gy) Radiation Therapy (RT) for Men with Localized Prostate Cancer
4. Biochemical Failure in Intermediate Risk Prostate Cancer: Then What? Long-Term Data from a Phase III Trial
5. PD-0497 Initial results for a state of the art “transferless” multi-modality imaging brachytherapy suite
6. Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: A phase I-II single institution trial
7. Infection after prostatic transrectal fiducial marker implantation for image guided radiation therapy
8. Focal HDR brachytherapy boost to stereotactic radiotherapy (fBTsRT) for prostate cancer: a phase II randomized controlled trial
9. Ultra-Hypo Fractionated Prostate IGRT with HDR Brachytherapy Boost as Compared to a Moderate-Hypo Fractionated Approach: Patient Reported Outcomes (PRO's) of a Phase Two Study Interim Analysis
10. Combined Risk Factors and Outcomes in High-Risk Prostate Cancer: Secondary Analysis of a Phase III Trial
11. Cardiovascular Causes of Death in Patients Treated for Localized Prostate Cancer
12. Salvage Prostate Brachytherapy in Radiorecurrent Prostate Cancer: An International Delphi Consensus Study
13. A Pilot Study of Salvage HDR Brachytherapy in Recurrent Prostate Cancer: 5 Year Toxicity and Outcomes
14. Ultra-Hypofractionated (UHF) Compared to Moderate-Hypofractionated (MHF) Prostate IGRT With HDR Brachytherapy Boost (BB): Four-Year Toxicities and Local Control
15. Primary Endpoint Analysis of a Randomized Phase III Trial of Hypofractionated vs. Conventional Post-Prostatectomy Radiotherapy: NRG Oncology GU003
16. PO-1320 Infectious Risk After Prostatic Transrectal Fiducial Marker Implantation in Radiation Therapy
17. OC-0106 US-guided EM tracked system compared to OncentraProstate for HDR brachytherapy: a first in-men study
18. OC-0101 17 years' of EBRT plus HDR brachytherapy boost in high risk localized prostate cancer patients
19. PO-0209 Practical considerations on the use of EM tracking technology for clinical HDR brachytherapy
20. PP-0156 HDR and LDR comparison as monotherapy in localized prostate cancer: PSA kinetic and late toxicity
21. Salvage Low Dose Rate Prostate Brachytherapy: Clinical Outcomes of a Phase II Trial for Local Recurrence after External Beam Radiotherapy (NRG/RTOG -0526)
22. Analysis of PSA Kinetics and Late Treatment Related Toxicity in a Phase 2 Randomized Pilot Study Comparing High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
23. OC-1030: Salvage LDR Prostate Brachytherapy: Results of NRG/RTOG-0526 Trial for Local Recurrence after EBRT
24. Guideline for testosterone recovery in localized prostate cancer treated with different ADT duration: Long-term data from two prospective randomized trials
25. IMAGE-Guided Brachytherapy for Primary Vaginal Cancers
26. Long-Term Results of NRG Oncology/RTOG 0321 A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiotherapy for Adenocarcinoma of the Prostate
27. Outcomes Based on Risk Factors in Intermediate Risk Prostate Cancer: a Secondary Analysis of a Randomized Phase III Trial
28. The Advantages of Trus-Based HDR Prostate Treatment When Compared to CT Planning
29. ULTRA-HYPO (UHF) Compared to Moderate-HYPO (MHF) Fractionated Prostate IGRT with HDR Brachytherapy BOOST: LONG TERM Toxicity, Acceptability and Efficiency of Delivery
30. Employment Outcomes for Recent Canadian Radiation Oncology Graduates
31. OC-0400 Are prostate contours affected by the RO's clinical experience in prostate HDR brachytherapy?
32. OC-0159 Long-Term Results of RTOG 0321: HDR Brachytherapy and External Beam Radiotherapy for Prostate Cancer
33. Short Term Androgen Deprivation Therapy Without or With Pelvic Lymph Node Treatment Added to Prostate Bed Only Salvage Radiotherapy: The NRG Oncology/RTOG 0534 SPPORT Trial
34. A Phase II Randomized Pilot Study Comparing High-Dose Rate Brachytherapy and Low-Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
35. Randomised Phase II Feasibility Trial of Image-guided External Beam Radiotherapy With or Without High Dose Rate Brachytherapy Boost in Men with Intermediate-risk Prostate Cancer (CCTG PR15/ NCT01982786)
36. Contouring and Target Variability in Vaginal Tumors Treated with MR-Based Interstitial Brachytherapy: A Multi-institutional Contouring Study
37. Significance of Testosterone Suppression in Localized Prostate Cancer Treated with Androgen Deprivation Therapy and Radiotherapy: Data from 2 Phase 3 Trials
38. The Risk of Second Malignancies after Seed Migration in Prostate Cancer Patients Treated With I-125 Free Seeds Brachytherapy
39. A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer after External Beam Radiation Therapy (NRG/RTOG0526): Initial Report of Late Toxicity Outcome
40. Does Delay From Prostate Cancer Diagnosis to Treatment With Permanent Seed Implantation Increase the Risk of Disease Recurrence in Men With Clinically Localized Prostate Cancer?
41. A Pilot Study of Salvage HDR Brachytherapy in Recurrent Prostate Cancer: Toxicity Profile and Outcomes
42. EP-1774: Randomized phase II trial of IGRT with or without HDR boost in intermediate-risk prostate cancer
43. PO-0930: CT to TRUS based Prostate HDR: what is the optimal dosimetric margin to use?
44. Stereotactic Ablative Radiotherapy Versus Low Dose Rate Brachytherapy or External Beam Radiotherapy: Propensity Score Matched Analyses of Canadian Data
45. Modeling Biochemical Relapse-Free Survival in Intraoperative Planned Low-Dose-Rate Prostate Brachytherapy: A Multicenter Cohort Analysis
46. Validation of a French-Canadian Version of the Expanded Prostate Cancer Index Composite Instrument (EPIC)
47. Second Malignancies as First Cause of Death in Localized Prostate Cancer Treated With Radiation Therapy: Data from Two Phase 3 Trials
48. Optogenetic Activation of Septal Glutamatergic Neurons Drive Hippocampal Theta Rhythms
49. Prognostic Groups for p16-Positive Oropharyngeal Squamous Cell Cancer (p16-OPSCC) Treated With Chemoradiation Therapy (CRT) in NRG Oncology/RTOG 0129 and 0522
50. Validation of NRG Oncology/RTOG 0129 Risk Groups for p16-Positive and p16-Negative Oropharyngeal Squamous Cell Cancer (OPSCC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.